SAN FRANCISCO--(BUSINESS WIRE)-- <\/p>\n
Great Basin Corporation, a privately-held molecular diagnostics company developing sample-to-result solutions, today presented initial data of its Candida assay during the Clinical MycologyDiagnosis, Treatment and Epidemiology (Division F) session at the American Society of Microbiology General Meeting in San Francisco. Currently under development, the assay can detect the most medically relevant Candida species within an hour from blood cultures taken from patients with fungal bloodstream infections (BSI), speeding diagnosis and appropriate treatment for better patient outcomes. <\/p>\n
Candidemia constitutes the fourth leading cause of hospital acquired BSI in the United States. Immuno-compromised patients, including transplant, HIV-infected, and chemotherapy patients, are at particularly high risk of fungal infections. <\/p>\n
We are very pleased about the growing body of data that demonstrates the efficacy of Great Basins technology, said Ryan Ashton, president and CEO, Great Basin Corporation. Great Basin is focused on developing cost-effective tests that markedly change the way clinicians diagnose the most virulent hospital acquired infections, such as Candida. We look forward to expanding our menu of available assays to support the continued adoption of our platform. <\/p>\n
Three additional posters featuring Great Basins technology were presented today during the Detection of C. difficile (Division C) session, including: <\/p>\n
In May, Great Basin received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its first molecular diagnostic test, which detects Clostridium difficile (C. diff), one of the most common and deadly hospital-acquired infections. The company also released this assay as a European CE-IVD product under the European Directive 98\/79\/EC on In Vitro Diagnostic Medical Devices. The test is being marketed in both the U.S. and the EU. <\/p>\n
The companys easy-to-use integrated cartridge system allows for more accurate and information-rich detection of infectious diseases, allowing providers to diagnose and define a clear treatment path sooner for improved patient outcomes, shorter hospital stays and significant cost savings. The companys goal is to deliver assays that can be performed in a CLIA-rated waived or moderately complex laboratory at a lower cost than other molecular diagnostic solutions. <\/p>\n
Great Basins technology entails an integrated disposable cartridge containing all necessary reagents and an inexpensive bench-top analyzer that executes the assay, interprets the results and provides electronic output to the clinician. The platform has several key advantages over other molecular solutions: <\/p>\n
About Great Basin Corporation <\/p>\n
Great Basin Corporation is a privately-held molecular diagnostics company that commercializes breakthrough, chip-based technologies. The company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. By providing more diagnostic data per sample, healthcare providers are able to treat patients with the right medication sooner, improving outcomes and reducing costs. The companys vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the companys website at http:\/\/www.gbscience.com<\/a>. <\/p>\n<\/p>\n Visit link: SAN FRANCISCO--(BUSINESS WIRE)-- Great Basin Corporation, a privately-held molecular diagnostics company developing sample-to-result solutions, today presented initial data of its Candida assay during the Clinical MycologyDiagnosis, Treatment and Epidemiology (Division F) session at the American Society of Microbiology General Meeting in San Francisco. Currently under development, the assay can detect the most medically relevant Candida species within an hour from blood cultures taken from patients with fungal bloodstream infections (BSI), speeding diagnosis and appropriate treatment for better patient outcomes. Continue reading
\nData Presented at the American Society for Microbiology General Meeting Demonstrates Specificity of Great Basin ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"